Lifeward Ltd Stock Price, News & Analysis

Lifeward (Nasdaq: LFWD) has received CE mark approval for its ReWalk 7 Personal Exoskeleton, enabling commercial sales in Europe. The seventh-generation device features advanced capabilities including cloud connectivity, push-button control, customizable walking speeds, and improved stairs/curbs navigation.

Europe represents 40% of Lifeward's exoskeleton sales, with Germany being the second-largest market globally. The company has established reimbursement agreements with major German insurers, including BARMER, covering approximately 45% of people with statutory health insurance in Germany.

Lifeward Ltd. (NASDAQ: LFWD) reported Q2 2025 financial results, showing mixed performance with revenue of $5.7 million, down 15% year-over-year but up 14% sequentially. The company achieved significant operational milestones, including FDA clearance for ReWalk 7 and record Medicare beneficiary placements.

Key financial metrics include a 43.9% gross margin and reduced quarterly cash burn to $3.9 million. The company reported a net loss of $6.6 million, or $0.58 per share. Lifeward appointed new leadership with Mark Grant as CEO and Almog Adar as CFO, while updating 2025 guidance to $24-26 million in revenue.

Notable achievements include successful transition to in-house manufacturing, expanded U.S. payer base, and positive Medicare rulings establishing ReWalk as "reasonable and necessary" for beneficiaries.

Lifeward (NASDAQ:LFWD), a medical technology company focused on transforming lives of people with physical limitations, has appointed Almog Adar as its new Chief Financial Officer. Adar, who previously served as the company's Vice President of Finance and Chief Accounting Officer, joined Lifeward in 2020 and has progressively taken on more senior roles within the finance organization.

Prior to Lifeward, Adar held controller positions at Infinya Recycling and Delta Galil Industries, and worked at Ernst & Young. He holds a Bachelor's degree in Accounting and Economics and is a Certified Public Accountant licensed by the Israeli Ministry of Justice.

Lifeward (NASDAQ: LFWD), a global leader in medical technology for people with physical limitations, has scheduled its second quarter 2025 financial results announcement for August 14, 2025, before market open.

The company will host a conference call and webcast at 8:30 a.m. EDT featuring CEO Mark Grant and VP of Finance Almog Adar. Investors can access the call through various toll-free numbers in the U.S., Germany, and Israel, or view the webcast through the company's investor relations website.

Lifeward Ltd. (Nasdaq: LFWD), a medical technology company, has expanded its distribution partnership with SportsMed Products Ltd. to include the United Arab Emirates and the entire Gulf Cooperation Council (GCC) region. The expansion will be managed through SportsMed's Dubai-based entity, SportsMed Performance Trading LLC.

SportsMed Products has been the exclusive AlterG dealer in the UK and Ireland since 2015, with a track record of selling over 300 AlterG devices. The company has already established a demo zone in Dubai featuring the latest AlterG NEO+ system, demonstrating their commitment to the GCC market expansion.

MedRhythms (NASDAQ:LFWD) has appointed Larry Jasinski as its new Chief Executive Officer, effective immediately. Jasinski, former CEO of Lifeward, brings over 30 years of executive leadership in medical devices and neurotechnology. Co-founder Brian Harris transitions to Chief Scientific Officer after successfully leading the company through product development, FDA listings, and CMS benefit category assignments.

The appointment comes as MedRhythms prepares for national expansion of its FDA-listed Class II devices: InTandem® for chronic stroke and Movive™ for Parkinson's disease. Under Jasinski's leadership, the company aims to accelerate market adoption of its prescription music platform and expand access to its neurotherapeutics for walking and mobility improvements.

Jasinski's track record includes leading Lifeward through a successful IPO and securing national reimbursement for the first exoskeleton system for spinal cord injury.

Lifeward (NASDAQ: LFWD), a medical technology company, has closed its previously announced public offering, raising $2.6 million through the sale of 4,000,000 ordinary shares at $0.65 per share. The offering includes warrants to purchase an additional 4,000,000 ordinary shares at an exercise price of $0.65, potentially providing another $2.6 million if fully exercised.

The company plans to use the proceeds for commercial efforts, working capital, and general corporate purposes. H.C. Wainwright & Co. served as the exclusive placement agent for the offering, which was conducted under an effective SEC registration statement.

Lifeward (NASDAQ: LFWD), a medical technology company, has announced the pricing of a $2.6 million public offering. The offering consists of 4,000,000 ordinary shares with accompanying warrants at a combined price of $0.65 per share and warrant.

The warrants will have an exercise price of $0.65, be immediately exercisable, and expire in five years. If fully exercised, they could generate an additional $2.6 million. H.C. Wainwright & Co. is serving as the exclusive placement agent. The company plans to use the proceeds for commercial efforts, working capital, and general corporate purposes, with closing expected around June 26, 2025.

Lifeward (NASDAQ:LFWD) announced a significant legal victory as an Administrative Law Judge (ALJ) ruled that the ReWalk Personal Exoskeleton must be covered by Medicare as a "reasonable and necessary" medical device for individuals with spinal cord injury (SCI). This ruling follows CMS's April 2024 decision establishing a Medicare reimbursement pathway for personal exoskeletons.

The decision reinforces the medical necessity of ReWalk's technology and is expected to influence coverage decisions by commercial insurers. The ReWalk 7, the company's latest innovation and the only personal exoskeleton capable of navigating stairs and curbs, received FDA clearance in March 2025 and is now commercially available in the United States.